1270 related articles for article (PubMed ID: 29180536)
41. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
[TBL] [Abstract][Full Text] [Related]
42. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
43. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
44. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.
Yu J; Wu X; Yan J; Yu H; Xu L; Chi Z; Sheng X; Si L; Cui C; Dai J; Ma M; Xu T; Kong Y; Guo J
J Hematol Oncol; 2018 Jan; 11(1):1. PubMed ID: 29298689
[TBL] [Abstract][Full Text] [Related]
45. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
[TBL] [Abstract][Full Text] [Related]
46. Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.
Landoni E; Fucá G; Wang J; Chirasani VR; Yao Z; Dukhovlinova E; Ferrone S; Savoldo B; Hong LK; Shou P; Musio S; Padelli F; Finocchiaro G; Droste M; Kuhlman B; Shamshiev A; Pellegatta S; Dokholyan NV; Dotti G
Cancer Immunol Res; 2021 Apr; 9(4):441-453. PubMed ID: 33547226
[TBL] [Abstract][Full Text] [Related]
47. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
[TBL] [Abstract][Full Text] [Related]
48. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
Louis CU; Savoldo B; Dotti G; Pule M; Yvon E; Myers GD; Rossig C; Russell HV; Diouf O; Liu E; Liu H; Wu MF; Gee AP; Mei Z; Rooney CM; Heslop HE; Brenner MK
Blood; 2011 Dec; 118(23):6050-6. PubMed ID: 21984804
[TBL] [Abstract][Full Text] [Related]
49. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.
Yankelevich M; Kondadasula SV; Thakur A; Buck S; Cheung NK; Lum LG
Pediatr Blood Cancer; 2012 Dec; 59(7):1198-205. PubMed ID: 22707078
[TBL] [Abstract][Full Text] [Related]
50. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Heczey A; Louis CU; Savoldo B; Dakhova O; Durett A; Grilley B; Liu H; Wu MF; Mei Z; Gee A; Mehta B; Zhang H; Mahmood N; Tashiro H; Heslop HE; Dotti G; Rooney CM; Brenner MK
Mol Ther; 2017 Sep; 25(9):2214-2224. PubMed ID: 28602436
[TBL] [Abstract][Full Text] [Related]
51. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M
Mount CW; Majzner RG; Sundaresh S; Arnold EP; Kadapakkam M; Haile S; Labanieh L; Hulleman E; Woo PJ; Rietberg SP; Vogel H; Monje M; Mackall CL
Nat Med; 2018 May; 24(5):572-579. PubMed ID: 29662203
[TBL] [Abstract][Full Text] [Related]
52. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
53. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
54. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
55. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2019; 10():1149. PubMed ID: 31178870
[TBL] [Abstract][Full Text] [Related]
56. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
57. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
58. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
59. Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.
Giardino Torchia ML; Gilbreth R; Merlino A; Sult E; Monks N; Chesebrough J; Tammali R; Chu N; Tong J; Meekin J; Schifferli K; Vashisht K; DaCosta K; Clarke L; Gesse C; Yao XT; Bridges C; Moody G
Cytotherapy; 2022 Jul; 24(7):720-732. PubMed ID: 35570170
[TBL] [Abstract][Full Text] [Related]
60. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]